Evidence map›Paper›PMID 41598156›Full record

ArticleMaterials (Basel, Switzerland)2026

Correction: Iqbal et al. Breast Cancer Inhibition by Biosynthesized Titanium Dioxide Nanoparticles Is Comparable to Free Doxorubicin but Appeared Safer in BALB/c Mice.

Haroon Iqbal, Anam Razzaq, Bushra Uzair, Noor Ul Ain, Shamaila Sajjad, Norah Ayidh Althobaiti, Aishah Eid Albalawi, Bouzid Menaa, Muhammad Haroon, Muslim Khan and 2 more

Abstract readPublished Erratum
PubMed Full text at PMC Publisher
In one paragraph

Article in Materials (Basel, Switzerland), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

12 authors.

Haroon IqbalCollege of Pharmaceutical Science, Soochow University, Suzhou 215123, China.ORCID 0000-0002-7908-8804
Anam RazzaqCollege of Pharmaceutical Science, Soochow University, Suzhou 215123, China.
Bushra UzairDepartment of Biological Sciences, International Islamic University, Islamabad 44000, Pakistan.ORCID 0000-0003-2181-6378
Noor Ul AinCollege of Pharmaceutical Science, Soochow University, Suzhou 215123, China.ORCID 0000-0003-0423-2661
Shamaila SajjadDepartment of Biological Sciences, International Islamic University, Islamabad 44000, Pakistan.ORCID 0000-0002-8739-3788
Norah Ayidh AlthobaitiDepartment of Biology, Faculty of Science and Humanities, Shaqra University, Al-Quwayiyah 11961, Saudi Arabia.ORCID 0000-0001-6893-5521
Aishah Eid AlbalawiDepartment of Biology, Faculty of Sciences, University of Tabuk, Tabuk 47731, Saudi Arabia.ORCID 0000-0002-7695-8691
Bouzid MenaaDepartment of Oncology and Nanomedicine, California Innovations Corporation, San Diego, CA 92037, USA.
Muhammad HaroonFaculty of Pharmacy, Gomal University, Dera Ismail Khan 29050, Pakistan.
Muslim KhanDepartment of Chemistry, Kohat University of Science and Technology, Kohat 26000, Pakistan.
Naveed Ullah KhanCollege of Pharmaceutical Science, Soochow University, Suzhou 215123, China.ORCID 0000-0002-3338-1642
Farid MenaaDepartment of Oncology and Nanomedicine, California Innovations Corporation, San Diego, CA 92037, USA.ORCID 0000-0002-0258-7322

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

In the original publication [...].

Identifiers

PMID41598156
PMCPMC12843021

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.